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Novelty and impact  
 
The ability of adoptively transferred T cells to expand, and home to tumors are essential steps 
for successful therapy. Using mouse models that differed in tumor burden, nature of targeted 
antigen and tumor location, we found that neither ignorance nor immunological exclusion 
prevented the in vivo response of transferred T cells. In contrast, functionally active T cells 
with low expression of the inhibitory receptor PD1 were mainly observed in the 
immunodeficient and target-antigen-negative tumor-bearing hosts. 
 
 3 
Abstract 
Activated T cells expressing endogenous or transduced TCRs are two cell types currently 
used in clinical adoptive T-cell therapy. The ability of these cells to recognize their antigen, 
expand, and traffic to the tumor site are the initial steps necessary for successful therapy. In 
this study, we used in vivo bioluminescent imaging (BLI) of Renilla luciferase (RLuc) 
expressing T cells to evaluate the ability of adoptively transferred T cells to survive, expand 
and home to tumor site in vivo. Using this method, termed RT-Rack (Rluc T cell tracking), we 
followed T-cell response against tumors in vivo. Expansion and homing of adoptively 
transferred T cells were antigen dependent, but independent of the host immune status. 
Moreover, we successfully detected T-cell response to small and large tumors, including 
autochthonous liver tumors. The adoptively transferred T cells were not ignorant or excluded 
in a partially tolerant host, which expressed low level of the target in the periphery. Using T 
cell receptor-engineered T cells, we showed the ability of these cells to respond in tumor-
bearing hosts by expanding and homing to the tumor site. In all these models, the host 
immune status, the nature of the tumor or of the antigen, the tumor size, and the presence of 
the targeted antigen in the periphery did not prevent the adoptively transferred T cells from 
responding by expanding and homing to the tumor. However, T cells had higher expression of 
the inhibitory receptor PD1 and reduced functional activity when a self-antigen was targeted. 
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Introduction 
Adoptive T-cell therapy is currently used in the clinic to treat malignancies 
1-7
. However, 
limited expansion, poor trafficking, and little accumulation of adoptively transferred T cells at 
the tumor site were suggested to constrain successful therapy. Using murine xenograft models, 
it has been demonstrated that enhanced trafficking of transferred T cells to the tumors can be 
obtained if appropriate chemokine’s receptors were introduced to these T cells 
8-10
. However, 
whether syngeneic tumors, including autochthonous tumors, are ignored or can be sufficiently 
detected in vivo using adoptively transferred T cells need to be evaluated. 
Different imaging techniques are available to detect cells in live mice with variable 
sensitivities and resolutions 
11
. BLI measures the emitted photons resulting from the 
enzymatic activity of a luciferase upon injection of its substrate. BLI is safer and more 
suitable than other small animal imaging techniques when mice are to be imaged repeatedly 
11-13
. BLI is sensitive and basically background free because mouse tissues do not produce 
detectable light 
13, 14
. Different cell populations expressing different luciferases can be imaged 
simultaneously and discriminated based on their substrate utilization and the wavelength of 
the emitted light 
15
. Furthermore, the acquisition time for BLI is short and up to 5 mice can be 
imaged in parallel, thus making BLI a high throughput in vivo imaging technique.  
In the field of cancer immunology, BLI is used to monitor tumor growth following ectopic 
luciferase expression in tumor cell lines. This technique is highly sensitive, enabling the 
detection of as few as 1000 tumor cells expressing FLuc 
16
 and 1000 T cells expressing RLuc 
17
. Interestingly, a clear linear correlation exists between the cell number and the imaged 
signal of T cells obtained from the RLuc mice 
17
. Recently, transgenic mouse models were 
established in which expression of a luciferase is linked to the oncogene indirectly by 
controlled co-expression or directly as a fusion protein 
18-22
.  
 5 
T cells are among the most sensitive cells of the immune system with their ability to detect 
trace amount of antigen 
23
. Others and we showed that adoptively transferred antigen-specific 
T cells can be detected in the transplanted tumor 
17, 24-28
. After injecting T cells expressing 
RLuc (RLuc-T), a strong T cell signal can be measured specifically from the target tumor site. 
Recently, more sophisticated and physiologically relevant mouse models were developed 
which include genetically induced or sporadic tumor mouse models. In these models, the 
oncogene is a self-antigen expressed at low level on healthy tissues, rendering these mice 
fully or partially tolerant toward the oncogene 
18-22, 29-35
. Adoptively transferred T cells failed 
to control tumor growth in these autochthonous, self-antigen induced tumor models 
19
. To 
evaluate whether immune exclusion mechanisms in these mice prevented the T cell response 
36
, we established an approach that we termed RT-Rack, for in vivo RLuc T cell tracking, 
combining the high sensitivity of T cells for their target antigen with the high sensitivity of 
BLI. We applied RT-Rack in various tumor-bearing mouse models, including mice with 
autochthonous tumors overexpressing a model self-antigen, to evaluate the capacity of 
adoptively transferred T cells to survive, recognize syngeneic tumor-derived antigens, expand, 
and traffic to tumor site in vivo. 
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Materials and Methods 
Cells 
EG.7F, EL-4F, 16.113F, MCA205-TagLuc and MCA205-MigFLuc were earlier described 
17, 
37
. 9.27P was established from 9.27 
31
 from long-term in vitro culture followed by in vivo 
passaging in C57BL/6 mice. 
Mice and tumor models 
C57BL/6 albino (B6/Albino) mice (C57Bl/6-Tyr
c-Brd
) were injected subcutaneously (s.c.) 
either with 2x10
6
 EG.7F or with 3-10x10
6
 9.27P cells. In the spectral unmixing experiments, 
B6/Albino mice were injected with 2x10
6
 EG.7F in the right side of the mouse and with 2x10
6
 
EL-4F in the left side of the mice. Rag
-/-
 albino mice (including Rag1
-/-
 or Rag2
-/-
 mice 
17
) 
were injected s.c. with either 3-10x10
6
 9.27P, or with 10x10
6
 16.113F cells. For the 
experimental metastasis model, Rag
-/-
 mice were injected intravenously (i.v.) with 2x10
5
 
MCA205-TagLuc or MCA205-MigFLuc cells 
38
. LTL mice were challenged s.c. with 3-10x
6
 
9.27P cells. LTL x Alb-Cre mice developing autochthonous HCC were described earlier 
19, 31
. 
Tumor mean diameter was measured along three orthogonal axes (a, b and c) by a digital 
caliper and calculated as earlier described 
39
. To be able to measure the smallest tumors in our 
study, tumor-injection-site was sprayed with 70% ethanol to enable the visualization of small 
palpable tumor nodules, which were then measured by electronic caliper. When no palpable 
tumor nodule was detected, similar procedures were followed using 70% ethanol spray to 
confirm the absence of a visible tumor nodule. Immunodeficient or immunosupressed mice 
(Rag
-/-
 mice or mice with a large tumor burden) received antibiotic treatment. All mouse 
studies were carried out in accordance with institutional, state, and federal (Landesamt für 
Arbeitsschutz, Gesundheitsschutz und technische Sicherheit, Berlin) guidelines. 
In vivo bioluminescence 
 7 
Renilla luciferase (RLuc) activity was detected by retro-orbital (ro.) injection of 100 µl of 
coelenterazine at 1 mg/ml (Biosynth), dissolved in 30% DMSO (Sigma-Aldrich,), 70% PBS 
(MgCl2 and CaCl2 free (Invitrogen)), followed by direct measurement with the IVIS
®
 200 
Imaging System for 1 minute, using small binning. Firefly luciferase (FLuc) activity was 
detected by injecting intravenously 100 µl of D-luciferin at 30 mg/ml (Biosynth), dissolved in 
PBS. Measurement was taken for 1 to 60 seconds using small or medium bining. Data 
analysis was performed using Living Image 2.6 and Living Image 4.0 software. The signal 
strength is depicted by a pseudocolor scale given in photon/second/cm
2
/steradian (p/s/cm
2
/sr). 
Simultaneous dual imaging 
EG.7F and EL.4F bearing B6/Albino mice were injected ro. with 100 µl of D-luciferin and, 7 
minutes later, with 100 µl of coelenterazine. Successive filtered images were taken at 480, 
500, 520, 540, 580, 600, 620 and 640 nm using small binning. Images taken from 480 nm to 
540 nm were acquired with an exposure time of one minute while the images taken from 560 
to 640 were acquired with an exposure time of 10 seconds. Alb-Cre x LTL mice were injected 
intravenously with 100 µl of substrate mixture containing 100 µg coelenterazine and 300 µg 
luciferine and imaged using similar setting as for EG.7F and EL.4F bearing B6/Albino mice, 
except that images taken from 560 to 640 nm were acquired with an exposure time of 1 
second. RLuc and FLuc light spectra were unmixed and analyzed using Living Image 4.0 
software. RLuc, FLuc and overlay signals are represented in red, green and orange 
respectively. 
RLuc-OT-I T cell activation and treatment 
Splenocytes from R-OT 
17
 transgenic mice were cultured in a 24-well plate at a concentration 
of 2x10
6
 cells/ml in presence of 1 µg/ml anti-CD3 antibody (BD Biosciences), 0.1 µg/ml anit-
CD28 antibody (BD Biosciences) and 1 µg/ml SIINFEKL peptide (Biosyntan) for 24 hours in 
complete RPMI medium (i.e. RPMI-1640 Glutamax-I supplemented with 50 µM β-
 8 
mercaptoethanol, 0.1 µg/ml gentamicin (all from Invitrogen) and 10% FCS (Pan-Biotech)). 24 
hours later, the medium was replaced with fresh medium containing 10 IU/ml IL-2 
(interleukin-2 (Novartis)) for 3 days. 10x10
6
 cells were then injected ro. (in 100 µl PBS) into 
EG.7F or EG.7F and EL-4F tumor-bearing B6/Albino mice. 
ChRLuc-TCRI T cell activation and treatment 
ChRLuc-TCRI 
17
 mice were immunized by intraperitoneal injection of 1x10
7
 16.113 cells. 
The spleens of these mice were harvested one week later and CD8
+
 T cells were purified by 
MACS using the CD8 negative isolation kit (Miltenyi). The purity was checked by FACS 
after staining for CD8 and Vβ7 (Biolegend) and was about 93±4%. 1x10
6
 cells were then 
injected ro. (in 100 µl PBS) into 9.27P tumor bearing mice, MCA205-TagLuc bearing mice, 
MCA205-MigFLuc tumor bearing mice or LTL x Alb-Cre mice. 
Retrovirus production 
50 µl Lipofectamin
TM
 2000 (Invitrogen) were diluted in 1250 µl Opti-MEM (Invitrogen), 
incubated for 5 minutes at room temperature (RT) and mixed with 1250 µl Opti-MEM 
containing 7.5 µg of pCL-ECO plasmid DNA (Imgenex) mixed with 7.5 µg of MP71 plasmid 
DNA encoding for either TCR I (Jukica, A et al, unpublished) or with pMIG 
5
 as a mock 
control. After 20 minutes of incubation at RT, the Lipofectamin
TM
-DNA mix was transferred 
onto monolayer of HEKT cells 
17
 (80% confluent) cultured in T75 flasks. Eight ml of 
complete DMEM medium (i.e. Dulbecco's Modified Eagle Medium supplemented with 50 
µM β-mercaptoethanol, 0.1 µg/ml gentamicin (all from Invitrogen) and 10% FCS (Pan-
Biotech)) were added and the cells were incubated overnight at 37°C. The medium was then 
replaced by fresh complete RPMI medium supplemented with 10 U/ml IL-2. Retrovirus-
containing supernatants were harvested 24h and 48 hours later. 
Retroviral transduction  
 9 
1x10
6 
cells/ml splenocytes from Rag-ChRLuc-OT-I mice 
17
 were activated in vitro in 24-well 
plates in complete RPMI medium supplemented with 1 µg/ml anti-CD3, 0.1 µg/ml anti-CD28 
antibodies, 1 µg/ml SIINFEKL and 10 IU/ml IL-2. 24 hours later, the splenocytes were 
transduced by spinocculation. Briefly, 70% of the medium was replaced by 1 ml of retrovirus-
containing supernatant supplemented with 10 µg/ml polybrene (Sigma). The plates were 
centrifuged at 2000 rpm for 90 minutes at 32°C. The medium was then directly exchanged 
with fresh complete RPMI containing 10 IU/ml IL-2 and cells were incubated at 37°C. A 
second transduction was done 24 hours later. One day after the last transduction, TCR I, TCR 
IV or GFP expression were measured by flow cytometry after co-staining with CD8 and 
Db/peptide I tetramers (Beckman Coulter). 16.113F-tumor bearing Rag
-/-
 mice were injected 
with 10
5
 to 10
6
 T cells ro. 
Immunohistology 
9.27P tumors were explanted from either Rag
-/-
, B6/Albino or LTL mice 2, 4 or 7 days after 
injection of 1x10
6
 in vivo activated ChRLuc-TCRI T cells. On days 4 and 7 after T-cell 
injection, lungs from 9.27P-bearing Rag
-/-
 mice were also explanted to confirm metastasis 
presence. One part of each tumor and lung was fixed in formalin and embedded in paraffin, 
another was cryopreserved, while the third part was used to isolate Tumor-infiltrating 
lymphocytes (TILs) for flow cytometry analyses. Paraffin embedded sections were stained for 
H&E, SV40 Large T and FLuc, while CD8 staining was performed on cryosections. Staining 
was performed as previously described 
19, 30, 31
. 
Isolation of tumor-infiltrating lymphocytes 
9.27P tumors were cut into small fragments and digested in 2-4 ml of PBS supplemented with 
78.8 µg/ml Liberase TM (Roche) and 30 U/ml DNase I (Roche) for 30 minutes at 37°C, 
followed by 20 minutes at room temperature. The suspension was then forced through a 40 
 10 
µm cell strainer and washed twice with PBS. The TILs were then separated from the cell 
suspension on ficoll gradient using Ficoll-Paque
TM 
 (GE). 
In vitro stimulation of TILs and splenocytes 
 TILs (0.5x10
6
) were cultured with naïve C57BL/6 splenocytes (2x10
6
) in presence of 1 µg/ml 
peptide I of SV40 Large T  or 1 µg/ml  gp33 peptides (Genquest). Splenocytes (2x10
6
) from 
tumor-bearing mice were cultured in presence of 1 µg/ml peptide I of SV40 Large T  or 1 
µg/ml  gp33 peptides. All cultures were done in 24-well plate over night at 37°C, in 1 ml 
complete RPMI medium, supplemented with 1 µl/ml Golgi Plug (BD). 
Flow cytometry of TILs and splenocytes 
TILs and splenocytes were stained ex vivo for cell surface expression of CD8, Vβ7, CD44, 
CD62L and PD-1 (Biolegend). After in vitro stimulation, TILs and splenocytes were stained 
for cell surface expression of CD8 and Vβ7, and intracellular accumulation of IFNγ and 
granzyme B (Biolegend). Intracellular staining of the cells was performed using the 
cytofix/cytoperm kit (BD Biosciences). Samples were acquired using either FACSCanto or 
LSR Fortesa operated by FACS Diva software (BD Biosciences). Data analysis was 
performed using FlowJo software (Tree Star). 
Statistical analysis 
Averages and standard deviations for light signals and flow cytometry values were calculated 
using Microsoft Excel 2007 (Microsoft Deutschland GmbH). 
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Results 
 T-cell expansion and homing are antigen dependent 
We have shown earlier that T cell accumulation into large tumors is antigen specific and leads 
to the detection of a strong and reliable signal by BLI and confirmed the homing by flow 
cytometry 
17
. In order to evaluate RT-Rack as a general method to measure T cell expansion 
and trafficking to tumor site in vivo, regardless of tumor burden, we first needed to visualize 
the co-localization of T cells and tumors by BLI. Therefore, EG.7F tumor cells expressing the 
model antigen ovalbumin (Ova) and its parental cell line EL-4F lacking Ova were injected on 
opposite flanks of C57BL/6 albino mice. Both tumor cell lines expressed FLuc, allowing us to 
follow their growth not only by tumor palpation but also by BLI. One week after tumor cell 
injection, at the day of ChRLuc-OT-I (R-OT) T cells injection, both EG.7F and EL-4F 
measured about 5 mm in mean diameter and had comparable FLuc signals (Fig. 1A). Within 
four days, EG.7F tumors were being rejected, as determined by a decrease in tumor size (data 
not shown). To analyze whether EG.7F and T cell signals co-localized, substrates for both 
FLuc and RLuc were injected simultaneously. In 4 of 7 mice, the EG.7F Fluc signal was no 
longer measurable at 640 nm (Fig. 1B, bottom middle panel), while the EG.7F FLuc signal 
could still be measured in the 3 remaining mice (Fig. 1B, bottom right panel). In the latter 
group, T cells and EG.7F signals co-localized, as shown by the orange color (Fig. 1C, right 
panel). On the opposite flank of the mice, where EL-4F tumor cells were injected, mainly the 
FLuc signal could be measured, as shown by a strong and predominantly green color. This 
confirms our earlier finding that T cell (RLuc) signal was clearly detectable from the antigen 
positive EG.7F tumor but not from the antigen negative EL-4F tumor (Fig. 1B). Interestingly, 
even in the group of mice where the EG.7F tumor signal disappeared within four days 
following T cell injection, a signal from the T cells was still detectable at the tumor site (Fig. 
1C, middle panel).  
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RT-Rack detected response to large, medium, and small tumors and to unpalpable tumor cell 
mass  
Having confirmed that RT-Rack can detect T-cell homing to antigen positive tumors, we 
evaluated the sensitivity of this approach by injecting RLuc-T cells into 4 groups of mice 
bearing decreasing EG.7F tumor burden or unpalpable EG.7F tumor cell mass. 
At the day of T cell injection, tumor cells masses were either unpalpable or had a mean 
diameter of 1, 7 or 10 mm. This size difference correlated with the tumor specific FLuc 
signals (Fig. 1D). Following the injection into the tumor bearing hosts, T cells expanded, 
homed, and accumulated in the antigen positive tumors within 3 to 4 days and remained there 
for 3 more days as shown by a stable T cell signal between days 3 and 6 after T cell injection 
(Fig. 1E). The T cell signal then decreased, corresponding to the contraction phase of a 
normal immune response (Fig. 1E). Despite the difference in the sizes of targeted tumors, R-
OT T cells expanded and homed to all these tumors (Fig. 1F), proving that RT-Rack is 
sensitive enough to detect T-cell response to small, and even unpalpable tumor cell masses in 
vivo.  
9.27P tumor cells express SV40 Large T (Tag), including epitope I which is recognized by 
ChRLuc-TCRI (R-TCRI) T cells 
31
. Groups of C57BL/6 mice were challenged s.c. with 9.27P 
tumor cells 14, 6 or 3 days before receiving R-TCRI T cells.  Similar to the data with EG.7F 
tumors, RT-Rack detected T cells accumulation in these tumors efficiently despite their size 
differences, which was confirmed by flow cytometry (Supplementary Fig. S1, S2B, and S2D).  
 
T cell expansion and homing was not limited by the host immune status  
After evaluating RT-Rack with a model tumor antigen, we tested whether this approach could 
be available for detecting T cell expansion and homing toward tumors expressing other 
 13 
epitopes, and whether the host immune status can influence RT-Rack’s ability to detect T cell 
response to tumors.  
LoxP-TagLuc (LTL) mice are transgenic for TagLuc, which enables the visualization of 
oncogene expression 
19
. The expression of TagLuc in these mice is blocked by a stop cassette 
flanked by 2 LoxP sites, which can be deleted in the presence of Cre recombinase. Due to the 
leakiness of the stop cassette, LTL mice express very low level of TagLuc ubiquitously, 
which is detectable by BLI and are tolerant to Tag expressing tumors 
19
. Immunocompetent 
C57BL/6, Tag-tolerant LTL or immunodeficient Rag
-/-
 mice were challenged s.c. with 9.27P 
tumor cells. Both control and tumor-bearing mice were injected 14-18 days later with R-TCRI 
T cells and imaged to detect T-cell signal. The 9.27P tumors grew faster in LTL (13.1 ± 1.4 
mm in mean diameter) and Rag
-/-
 mice (12.3 ± 1.9 mm in mean diameter, compared to 7.9 ± 
2.1 mm in mean diameter in C57BL/6 mice at day of treatment), probably due to the immune 
deficient or Tag tolerant environments. Therefore, these tumors were larger at these various 
imaging time points. R-TCRI T cells expanded and homed to the tumor sites in Rag
-/-
, LTL 
and C57BL/6 mice (Fig. 2A-B and Supplementary Fig. S2A-C). As LTL mice have a black 
fur, the T cell light signal as well as the background signal are lower in these mice as 
compared to the albino Rag
-/-
 and C57BL/6 mice 
19
. Similar data were obtained by flow 
cytometry of TILs from tumors explanted from LTL and C57BL/6 mice and by 
immunohistochemistry for sections from tumors explanted from Rag
-/-
 mice (Supplementary 
Fig. S2D-G). Moreover, the kinetics of T cell accumulation was similar in Rag
-/-
 and 
C57BL/6 mice, starting at day 3 and peaking at day 6 (Fig. 2C). However, T cells proliferated 
more in Rag
-/-
 mice, leading to higher signal from whole body (Fig. 2D) and secondary 
lymphoid organs (Fig. 2A-B) from these mice compared to C57BL/6 mice. In addition to the 
signals detected from the tumor and presumably secondary lymphoid organs, a specific T-cell 
signal was measured from the lung of the immunodeficient mice (Fig. 2B), most likely due to 
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T cell accumulation at the site of metastatic lesions. This was confirmed by 
immunohistochemistry, following staining for Tag in the lung sections from mice that 
received tumor challenge as compared to unchallenged mice (Fig 2E). 
Interestingly, in Fig. 2B, a strong signal was imaged at the tumor rim but not from the central 
area. Two main reasons can explain this. The first is the necrosis in the center of the tumor, 
which leads to the lack of live cells expressing the targeted antigen (H2-D
b
-presented Tag 
epitope I). The second is T-cell infiltration that is limited to the tumor edge and lack of 
infiltration of live tumor center. We have earlier shown that necrosis of the tumor center is 
induced following adoptive T cell therapy of large tumors in immunodeficient mice 
37
. To 
better investigate this, we have analyzed sections of these tumors by immunohistochemistry. 
Our data confirmed that while the tumor center was composed of mainly dead cells, the T 
cells co-localized at the tumor edge with live tumor cells (Fig. 2F).  
 
Adoptively transferred T cells responded to experimental metastases 
Minimal residual and disseminated metastatic tumors develop at early stages of tumor 
development and throughout its various stages, which contribute to the high mortality rate of 
cancer patients 
22, 40
. To evaluate whether RT-Rack can detect T-cell response to metastatic 
lesions, we developed an experimental bioluminescence model mimicking metastasis by 
injecting Rag
-/-
 mice intravenously with MCA205-TagLuc, a fibrosarcoma derived from the 
tumor cell line MCA205 by transfection with a plasmid expressing Tag fused to FLuc 
(TagLuc) 
37
. Experimental metastases formed within 4-7 days after tumor cell injection as 
detected by the FLuc activity from the lungs area (Fig. 3A-B). The presence of tumor nodules 
in the lungs was confirmed ex vivo by BLI (Fig. 3E) and by immunohistochemistry 
(Supplementary Fig. S3). 
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Five days following tumor cell injection, R-TCRI T cells were injected and mice were then 
imaged daily for the detection of T-cell signal. T cells expanded and accumulated in the lung 
area in tumor-bearing mice whereas no specific signal was detectable from tumor free control 
mice (Fig. 3C-F). Six days after T cell injection, mice were sacrificed and the lungs were 
imaged ex vivo to confirm the presence of T cells in the tumor-bearing lungs (Fig. 3F). 
T cells, when injected i.v., reach the lungs before continuing to circulate in the blood 
41
. To 
exclude the possibility that the T cell signal measured from the lung was due to an unspecific 
accumulation in this organ, Rag
-/-
 mice were injected either with MCA205-TagLuc or with a 
control MCA205-MigFLuc tumor cells lacking the Tag protein. Upon injection of R-TCRI T 
cells, only mice bearing Tag-expressing tumors showed RT-Rack signal from the lung (Fig. 
3G). This indicates that R-TCRI T cells expansion and accumulation at the site of metastases 
is antigen specific. Ex vivo imaging of the lungs at the peak of the signal intensity (day 6) 
confirmed the presence of R-TCRI T cells only when the cognate antigen was expressed by 
the tumor cells (Fig. 3H). 
 
Adoptively transferred T cells responded to autochthonous hepatocellular carcinoma  
We have earlier shown that crossing LTL mice with Albumin-Cre (Alb-Cre) mice leads to 
recombination in the liver and development of hepatocellular carcinoma (HCC) 
19
.  
Mice transgenic for LTL and Alb-Cre as well as their control littermates (single transgenic or 
wild type mice) were imaged for FLuc activity to detect leakiness and HCC development. A 
strong signal could be measured from the liver of the LTL x Alb-Cre double transgenic mouse 
(Fig. 4A), indicating HCC development. The leakiness of the stop cassette, resulting in a 
weak expression of the transgene, could be measured only when the exposure time was 
increased from 1 second to 1 minute (Fig. 4A). R-TCRI T cells were injected into these mice 
and their survival, expansion and accumulation were followed over time by BLI. T cells 
 16 
survived, expanded and preferentially accumulated at the liver site despite the weak 
expression of TagLuc in several normal tissues (Fig.4B, D). A weak T cell signal was 
nevertheless detected in these tissues in both LTL and LTL x Alb-Cre mice (Fig. 4E). 
Imaging FLuc and RLuc signals simultaneously confirmed the co-localization of the signals 
from tumor and T cells (depicted in orange in Fig. 4C). Moreover, when injected in mice 
bearing different tumor burden, T cell accumulation in HCC correlated with tumor burden 
(Fig. 4 F-H). 
 
Adoptively transferred TCRI-engineered T cell responded to Tag expressing tumors 
So far, we have evaluated the ability of T cells expressing endogenous TCR to expand and 
home to tumors in various mouse models. Therapeutic T cells can be produced from 
polyclonal T cell population by expressing a new TCR by transduction. Therefore, we 
evaluated whether RT-Rack can detect the response of these engineered T cells to tumors in 
vivo. 
Rag
-/-
 mice were injected subcutaneously with the Tag expressing tumor cell line 16.113F 
17
. 
Mice were treated 49 days later, when the tumor measured 3 mm in mean diameter, with R-
OT T cells transduced with Tag specific TCRI or with pMIG (as a mock control) retroviral 
vectors. On average, 25-30% of the T cells were successfully transduced as shown by flow 
cytometry analysis after staining with D
b
/peptide I multimers specific for TCRI or by 
measuring GFP expression of MIG (28% and 32%, respectively) (Fig. 5A). The long waiting 
period before T cell injection enabled us to exclude the effects of artifactual T cell stimulation 
by inflammation or cross priming caused by tumor inoculum and tumor cell death 
29
. These 
effects were reported to induce better response by the T cells 
29
. T-cell expansion and 
accumulation were followed in vivo by imaging the mice for RLuc activity. TCRI transduced 
T cells survived, expanded and accumulated at the tumor site as shown by the strong signals 
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measured 7 and 9 days after T cell injection, whereas no light signal was observed at the 
tumor site in mice injected with mock-transduced T cells (Fig. 5B-C). Thus, RT-Rack can be 
combined with engineered T cells to evaluate T cell response in vivo. 
 
T cells from LTL mice have reduced functional activity and increased expression of PD1 
We have analyzed the profile of the T cell response in the tumor-bearing as well as tumor free 
Rag
-/-
, C57BL/6 and LTL mice. Mice were challenged with 9.27P tumor cells and 2 weeks 
later received adoptive transfer of R-TCRI. One week later, splencocytes and TILs were 
isolated and analyzed for expression of CD44, CD62L and PD1 
42
 by flow cytometry. 
Alternatively these T cells were stimulated over night by their cognate H2-D
b
-presented 
epitope I peptide and stained for their ability to produce IFN-γ and granzyme B. Most TILs 
showed an effector memory phenotype, regardless of the immunological status or the 
expression of the targeted antigen (Supplementary Fig. S4). We found that T cells isolated 
from tumors or spleens of tumor-bearing Rag
-/-
 mice have the highest effector function (IFN-γ 
and granzyme B production) and the lowest expression of the inhibitory receptor PD-1 (Fig. 
6). In contrast, T cells isolated from tumors or spleens of tumor-bearing LTL mice showed the 
lowest effector function (IFN-γ and granzyme B production) and the highest expression of the 
inhibitory receptor PD-1 (Fig. 6). 
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Discussion 
Antigen recognition, expansion, and homing of antigen-specific T cells to tumor sites are the 
initial steps necessary for the success of adoptive T cell therapy. In this study, we described 
an approach to detect the response of adoptively transferred T cells over time in vivo. We 
analyzed in vivo the impact of the antigen environment, the influence of tumor origin, and the 
nature of TCR expression on T-cell response by BLI. Using RLuc transgenic T cells enabled 
us to follow the T-cell signal repeatedly for 2-3 weeks in vivo. Antigen specific RLuc T cells 
homed to antigen positive, but not antigen negative tumors. The host environment contributes 
to the ability of T cells to survive and expand 
43
. Nevertheless, RT-Rack detected T-cell 
response independently of the host immune status. At the peak of the signal, we could detect 3 
to 4 fold higher signal from the tumor site in the immunodeficient as compared to the 
immunocompetent mice. The more prominent T cell accumulation at the tumor sites in Rag
-/-
 
mice might have reflected the difference in the tumor size between Rag
-/-
 and C57BL/6 mice 
or lack of competition by the endogenous T cells. Occasional signals measured from the 
secondary lymphoid organs could be due to T cell accumulation in these organs or to 
detection of metastases. Intravenous injection of the fibrosarcoma cell line MCA205 
experimentally mimicked metastases development 
38
. RT-Rack detected T-cell response to 
these tumors only when the MCA205 expressed the target antigen Tag.  
RT-Rack measured T-cell response not only to transplantable tumors and experimental 
metastasis, but also toward autochthonous tumors expressing the targeted Tag as a model of 
self-antigen.  LTL x Alb-Cre mice develop HCC after a latency of 3 to 4 months 
19
. HCC in 
these mice expressed FLuc enabling the confirmation of T-cell homing to the tumor by RT-
Rack. Following injection, RT-Rack localized T-cells homing to the HCC, even as the target 
antigen was also expressed at low level by normal non-transformed cells 
19
, a characteristic 
common for most of the targeted cancer antigens 
44
. Without pre-treatment of the host, such as 
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lymphodepletion, T cells successfully expanded and homed to the primary tumor. The 
presence of the targeted Tag at low level in the periphery did not prevent preferential T cell 
recognition of the tumor. This excludes the possibility that the tumor and the immunotolerant 
environment of the host toward Tag-specific T cells lead to T cell exclusion in this model, a 
mechanism proposed to explain the failure of therapeutic T cells in controlling tumor growth 
36
. Notably, the intensity of the RLuc signal, representing T cell homing to the tumor, 
correlated with tumor burden. Interestingly, T cells were able to survive and detect an 
overexpressed self-antigen in this HCC mouse model, where the tumor is growing in an organ 
described as a graveyard for T cells 
45
. In Fig 4C, the T-cell signal was detected from the 
whole tumor area. This signal co-localized, to a similar extent, with the tumor-cell signal in 
some areas (depicted by the orange color) or was stronger or weaker in other areas of the liver. 
This variation might reflect the density of the antigen or the cells presenting it at the imaging 
time. Nonetheless, the T-cell signal emanated from the whole area where the tumor signal did. 
T cells transduced to express the TCR specific for the peptide I of Tag successfully expanded 
and homed to tumors. It is therefore possible to apply the RT-Rack technique to study other 
tumor models, where TCR transgenic mice are not yet available, and possibly to other 
diseases, such as viral, bacterial, or parasitic infections 
3, 6
. Moreover, the T cell engineering 
technology enables the possibility of the targeting of several epitopes or tumor associated 
antigens in parallel, for example by using TCRs recognizing two different epitopes of the 
same antigen. Following therapy with these T cells, it will be possible to compare in vivo the 
T cell response guided by either receptors. 
The background light signal of RLuc substrate, emanating from the liver, was reported to be 
due to the autooxidation of the substrate 
46
. Nevertheless, the signal was far weaker than the 
specific RT-Rack signal from the T cells accumulating in the tumor. 
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We evaluated the phenotypic and functional characteristic of the TILs isolated from tumor 
growing in immunodeficient antigen-negative Rag
-/-
 mice as compared to immunocompetent 
mice expressing (LTL) or not (C57BL/6) the targeted tumor antigen. Our data indicated that 
TILs from the tumors explanted from antigen-negative and immunodeficient mice have the 
highest effector function and the lowest expression level of the inhibitory receptor PD1. In 
contrast, TILs from the tumors explanted from antigen-expressing and immunocompetent 
mice have the highest effector function and the lowest expression level of the inhibitory 
receptor PD1. We have earlier shown that Tag-expressing tumors can be rejected by adoptive 
T cell therapy in Rag
-/-
, but not LTL mice 
17, 19
. Therefore, our data show that the limiting step 
in this model of adoptive T cell therapy is not survival, target antigen recognition, 
proliferation or homing of the adoptively transferred T cells. Rather, the limiting step is the 
ability of these cells to differentiate into fully effector T cells that express low level of the 
inhibitory receptor PD1. 
 
 
Acknowledgement 
The authors thank Dr. G. Willimsky and B. Horrigan for the critical reading of this 
manuscript. We also thank M. Hensel, S. Spieckermann, M. Babka, and S. Kupsch for their 
excellent technical assistance and D. Tarak and R. Manteufel for their help by taking care of 
the mice. This work was supported by the Deutsche Forschungsgemeinschaft Transregio-
Sonderforschungsbereich TR36 (J. C. and T. B.), the Deutsche Krebshilfe (J. C. and T. B.) 
and the European Community program FP6 “ATTACK” (T. B.). 
 
 21 
References 
 
1. Jensen MC, Riddell SR. Design and implementation of adoptive therapy with chimeric 
antigen receptor-modified T cells. Immunol Rev 2014;257: 127-44. 
2. Kunert A, Straetemans T, Govers C, Lamers C, Mathijssen R, Sleijfer S, Debets R. TCR-
Engineered T Cells Meet New Challenges to Treat Solid Tumors: Choice of Antigen, T Cell 
Fitness, and Sensitization of Tumor Milieu. Front Immunol 2013;4: 363. 
3. Restifo NP, Dudley ME, Rosenberg SA. Adoptive immunotherapy for cancer: harnessing 
the T cell response. Nat Rev Immunol 2012;12: 269-81. 
4. Rosenberg SA. Raising the bar: the curative potential of human cancer immunotherapy. Sci 
Transl Med 2012;4: 127ps8. 
5. Charo J, Finkelstein SE, Grewal N, Restifo NP, Robbins PF, Rosenberg SA. Bcl-2 
overexpression enhances tumor-specific T-cell survival. Cancer Res 2005;65: 2001-8. 
6. Morgan RA, Dudley ME, Wunderlich JR, Hughes MS, Yang JC, Sherry RM, Royal RE, 
Topalian SL, Kammula US, Restifo NP, Zheng Z, Nahvi A, et al. Cancer regression in 
patients after transfer of genetically engineered lymphocytes. Science 2006;314: 126-9. 
7. Blohm U, Potthoff D, van der Kogel AJ, Pircher H. Solid tumors "melt" from the inside 
after successful CD8 T cell attack. Eur J Immunol 2006;36: 468-77. 
8. Di Stasi A, De Angelis B, Rooney CM, Zhang L, Mahendravada A, Foster AE, Heslop HE, 
Brenner MK, Dotti G, Savoldo B. T lymphocytes coexpressing CCR4 and a chimeric antigen 
receptor targeting CD30 have improved homing and antitumor activity in a Hodgkin tumor 
model. Blood 2009;113: 6392-402. 
9. Kershaw MH, Wang G, Westwood JA, Pachynski RK, Tiffany HL, Marincola FM, Wang E, 
Young HA, Murphy PM, Hwu P. Redirecting migration of T cells to chemokine secreted from 
tumors by genetic modification with CXCR2. Hum Gene Ther 2002;13: 1971-80. 
10. Craddock JA, Lu A, Bear A, Pule M, Brenner MK, Rooney CM, Foster AE. Enhanced 
tumor trafficking of GD2 chimeric antigen receptor T cells by expression of the chemokine 
receptor CCR2b. J Immunother 2010;33: 780-8. 
11. Lyons SK. Advances in imaging mouse tumour models in vivo. J Pathol 2005;205: 194-
205. 
12. Willmann JK, van Bruggen N, Dinkelborg LM, Gambhir SS. Molecular imaging in drug 
development. Nat Rev Drug Discov 2008;7: 591-607. 
13. O'Neill K, Lyons SK, Gallagher WM, Curran KM, Byrne AT. Bioluminescent imaging: a 
critical tool in pre-clinical oncology research. J Pathol 2010;220: 317-27. 
14. Zhao H, Doyle TC, Coquoz O, Kalish F, Rice BW, Contag CH. Emission spectra of 
bioluminescent reporters and interaction with mammalian tissue determine the sensitivity of 
detection in vivo. J Biomed Opt 2005;10: 41210. 
15. Gammon ST, Leevy WM, Gross S, Gokel GW, Piwnica-Worms D. Spectral unmixing of 
multicolored bioluminescence emitted from heterogeneous biological sources. Anal Chem 
2006;78: 1520-7. 
16. Edinger M, Cao YA, Hornig YS, Jenkins DE, Verneris MR, Bachmann MH, Negrin RS, 
Contag CH. Advancing animal models of neoplasia through in vivo bioluminescence imaging. 
Eur J Cancer 2002;38: 2128-36. 
17. Charo J, Perez C, Buschow C, Jukica A, Czeh M, Blankenstein T. Visualizing the 
dynamic of adoptively transferred T cells during the rejection of large established tumors. Eur 
J Immunol 2011;41: 3187-97. 
18. Vooijs M, Jonkers J, Lyons S, Berns A. Noninvasive imaging of spontaneous 
retinoblastoma pathway-dependent tumors in mice. Cancer Res 2002;62: 1862-7. 
 22 
19. Buschow C, Charo J, Anders K, Loddenkemper C, Jukica A, Alsamah W, Perez C, 
Willimsky G, Blankenstein T. In vivo imaging of an inducible oncogenic tumor antigen 
visualizes tumor progression and predicts CTL tolerance. J Immunol 2010;184: 2930-8. 
20. Liao CP, Zhong C, Saribekyan G, Bading J, Park R, Conti PS, Moats R, Berns A, Shi W, 
Zhou Z, Nikitin AY, Roy-Burman P. Mouse models of prostate adenocarcinoma with the 
capacity to monitor spontaneous carcinogenesis by bioluminescence or fluorescence. Cancer 
Res 2007;67: 7525-33. 
21. Lyons SK, Meuwissen R, Krimpenfort P, Berns A. The generation of a conditional 
reporter that enables bioluminescence imaging of Cre/loxP-dependent tumorigenesis in mice. 
Cancer Res 2003;63: 7042-6. 
22. Edinger M, Cao YA, Verneris MR, Bachmann MH, Contag CH, Negrin RS. Revealing 
lymphoma growth and the efficacy of immune cell therapies using in vivo bioluminescence 
imaging. Blood 2003;101: 640-8. 
23. Davis MM, Krogsgaard M, Huse M, Huppa J, Lillemeier BF, Li QJ. T cells as a self-
referential, sensory organ. Annu Rev Immunol 2007;25: 681-95. 
24. Dubey P, Su H, Adonai N, Du S, Rosato A, Braun J, Gambhir SS, Witte ON. Quantitative 
imaging of the T cell antitumor response by positron-emission tomography. Proc Natl Acad 
Sci U S A 2003;100: 1232-7. 
25. Kim D, Hung CF, Wu TC. Monitoring the trafficking of adoptively transferred antigen- 
specific CD8-positive T cells in vivo, using noninvasive luminescence imaging. Hum Gene 
Ther 2007;18: 575-88. 
26. Kircher MF, Allport JR, Graves EE, Love V, Josephson L, Lichtman AH, Weissleder R. 
In vivo high resolution three-dimensional imaging of antigen-specific cytotoxic T-lymphocyte 
trafficking to tumors. Cancer Res 2003;63: 6838-46. 
27. Su H, Chang DS, Gambhir SS, Braun J. Monitoring the antitumor response of naive and 
memory CD8 T cells in RAG1-/- mice by positron-emission tomography. J Immunol 
2006;176: 4459-67. 
28. Boissonnas A, Combadiere C, Lavergne E, Maho M, Blanc C, Debre P, Combadiere B. 
Antigen distribution drives programmed antitumor CD8 cell migration and determines its 
efficiency. J Immunol 2004;173: 222-9. 
29. Schreiber K, Rowley DA, Riethmuller G, Schreiber H. Cancer immunotherapy and 
preclinical studies: why we are not wasting our time with animal experiments. Hematol Oncol 
Clin North Am 2006;20: 567-84. 
30. Willimsky G, Czeh M, Loddenkemper C, Gellermann J, Schmidt K, Wust P, Stein H, 
Blankenstein T. Immunogenicity of premalignant lesions is the primary cause of general 
cytotoxic T lymphocyte unresponsiveness. J Exp Med 2008;205: 1687-700. 
31. Willimsky G, Blankenstein T. Sporadic immunogenic tumours avoid destruction by 
inducing T-cell tolerance. Nature 2005;437: 141-6. 
32. Czeh M, Loddenkemper C, Shalapour S, Schon C, Robine S, Goldscheid E, Stein H, 
Schuler T, Willimsky G, Blankenstein T. The immune response to sporadic colorectal cancer 
in a novel mouse model. Oncogene 2010;29: 6591-602. 
33. Huettner CS, Zhang P, Van Etten RA, Tenen DG. Reversibility of acute B-cell leukaemia 
induced by BCR-ABL1. Nat Genet 2000;24: 57-60. 
34. Jonkers J, Berns A. Conditional mouse models of sporadic cancer. Nat Rev Cancer 2002;2: 
251-65. 
35. Herzig M, Christofori G. Recent advances in cancer research: mouse models of 
tumorigenesis. Biochim Biophys Acta 2002;1602: 97-113. 
36. Gajewski TF, Schreiber H, Fu YX. Innate and adaptive immune cells in the tumor 
microenvironment. Nat Immunol 2013;14: 1014-22. 
 23 
37. Anders K, Buschow C, Herrmann A, Milojkovic A, Loddenkemper C, Kammertoens T, 
Daniel P, Yu H, Charo J, Blankenstein T. Oncogene-Targeting T Cells Reject Large Tumors 
while Oncogene Inactivation Selects Escape Variants in Mouse Models of Cancer. Cancer 
Cell 2011;20: 755-67. 
38. Wei S, Shreiner AB, Takeshita N, Chen L, Zou W, Chang AE. Tumor-induced immune 
suppression of in vivo effector T-cell priming is mediated by the B7-H1/PD-1 axis and 
transforming growth factor beta. Cancer Res 2008;68: 5432-8. 
39. Charo J, Ciupitu AM, Le Chevalier De Preville A, Trivedi P, Klein G, Hinkula J, 
Kiessling R. A long-term memory obtained by genetic immunization results in full protection 
from a mammary adenocarcinoma expressing an EBV gene. J Immunol 1999;163: 5913-9. 
40. Lacroix J, Doeberitz MK. Technical aspects of minimal residual disease detection in 
carcinoma patients. Semin Surg Oncol 2001;20: 252-64. 
41. Mandl S, Schimmelpfennig C, Edinger M, Negrin RS, Contag CH. Understanding 
immune cell trafficking patterns via in vivo bioluminescence imaging. J Cell Biochem Suppl 
2002;39: 239-48. 
42. Fife BT, Bluestone JA. Control of peripheral T-cell tolerance and autoimmunity via the 
CTLA-4 and PD-1 pathways. Immunol Rev 2008;224: 166-82. 
43. Gattinoni L, Finkelstein SE, Klebanoff CA, Antony PA, Palmer DC, Spiess PJ, Hwang 
LN, Yu Z, Wrzesinski C, Heimann DM, Surh CD, Rosenberg SA, et al. Removal of 
homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively 
transferred tumor-specific CD8+ T cells. J Exp Med 2005;202: 907-12. 
44. Cheever MA, Allison JP, Ferris AS, Finn OJ, Hastings BM, Hecht TT, Mellman I, 
Prindiville SA, Viner JL, Weiner LM, Matrisian LM. The prioritization of cancer antigens: a 
national cancer institute pilot project for the acceleration of translational research. Clin 
Cancer Res 2009;15: 5323-37. 
45. Crispe IN, Dao T, Klugewitz K, Mehal WZ, Metz DP. The liver as a site of T-cell 
apoptosis: graveyard, or killing field? Immunol Rev 2000;174: 47-62. 
46. Otto-Duessel M, Khankaldyyan V, Gonzalez-Gomez I, Jensen MC, Laug WE, Rosol M. 
In vivo testing of Renilla luciferase substrate analogs in an orthotopic murine model of human 
glioblastoma. Mol Imaging 2006;5: 57-64. 
 
 
 
 24 
Figure Legends 
 
Figure 1: T-cell proliferative and homing responses measured by RT-Rack are antigen 
dependent and can be evoked by small or unpalpable tumor masses. (A) Seven days after 
injection of antigen-expressing EG.7F (+) and antigen-negative EL-4F (-) tumors cells on 
opposite sites, tumor-bearing and control tumor-free mice were imaged for tumor signal. (B-C) 
Mice were then injected with R-OT T cells and imaged 4 days later simultaneously for tumor 
and T cell signals. (C) Overlay of tumor and T-cell signals is shown in orange. (D-F) Groups 
of C57BL/6 mice were injected s.c. with EG.7F at 10, 8, 5 or 3 days before T cell injection. 
(D) Average FLuc tumor signals ± standard deviation from the 4 different groups, 3 days 
before T cell injection, with their corresponding tumor size at day of treatment indicated at the 
abscissa. (E) Mice from (D) were either kept untreated (open symbols, no T) or were injected 
with R-OT T cells (closed symbols, T) and imaged for T cell signal over time. At the 
treatment day, tumors measured 10 mm (■), 7 mm (♦), 1 mm (▲) in mean diameter or were 
unpalpable (●). The background signal for FLuc (tumor cells) and RLuc (T cells) is set as 
abscissa. (F) T cell signal from a representative mouse from each group imaged at day 6 after 
T cell injection is shown. Images were acquired for 1 min. using medium binning (n=4-5 mice 
per group). The signal intensity is shown as p/s/cm
2
/sr and depicted by a pseudocolor scale. 
 
Figure 2: RT-Rack detects T-cell response to tumors in immunodeficient as well as 
immunocompetent mice. (A-B) 9.27P s.c. tumor-bearing C57BL/6 (A) and Rag
-/-
 (B) mice 
as well as tumor-free littermates (control) were injected with R-TCRI T cells or kept untreated 
and imaged at the indicated days for RLuc activity (T cells). The signal strength is depicted by 
a pseudocolor scale. Images were acquired for 1 min., using small binning. (C-D) RLuc signal 
over time at the tumor site (C) or total mouse body (D) of untreated (open symbols, no T) and 
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T cell treated (closed symbols, T) Rag
-/-
 (■) and C57BL/6 (▲) mice. Data are representative 
of 2 independently performed experiments (n=4-7 mice per group). The signal intensity is 
shown as p/s/cm
2
/sr and depicted by a pseudocolor scale. (E) Sections from lungs of 9.27P s.c. 
tumor-bearing Rag
-/-
 and tumor-free littermates (control) were stained for Tag on 4 and 7 days 
after T cell injection. The photographs are representative of two independently performed 
experiments. The scale bar corresponds to 100 µm. (F) Seven days after T cell injection, 
sections of 9.27P tumors from Rag
-/-
 mice were stained for CD8. Shown are the representative 
photographs of the CD8 staining. CD8 T cell (red) distribution in the tumor is shown in the 
left panel. The dotted line separates the rim, where the T cells are present, from the necrotic 
(N) center of the tumor. The scale bar corresponds to 100 µm. The right panel shows the CD8 
staining at the rim of the tumor at a higher magnification, with the scale bar corresponding to 
25 µm. 
  
Figure 3: RT-Rack detects T-cell response to experimental MCA-TagLuc metastases. (A) 
Rag
-/- 
mice challenged with MCA205-TagLuc cells were imaged for FLuc activity to detect 
metastases formation. Shown is tumor signal over time and change in FLuc (tumor) signal 
(p/s) from the lung area of the mouse is plotted in the graph. (B) One day before T cell 
injection (4 days after injection of MCA205-TagLuc cells), mice were imaged for FLuc 
activity to detect the metastases. On treatment day, mice received R-TCRI T cells. (C) RLuc 
activity was measured on days 2-6. Shown are two representative mice with either uni- or 
bilateral metastases. (D) T cell signal in the lung over time from tumor bearing (closed 
symbol, n=6) and tumor free (open symbol, n=1) mice. (E-F) 6 days after T cell transfer, mice 
were sacrificed and the lungs were imaged ex vivo for RLuc activity (F). As a control, one 
mouse without T cell treatment was sacrificed at the same time and the lung was imaged for 
FLuc activity (E). (G) Rag
-/-
 mice with MCA205-TagLuc tumors (Tag +, n=5) or MCA205-
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MigFLuc tumors (Tag -, n=3) or without tumor (negative control, n=5) were injected with R-
TCRI T cells. RLuc activity was measured 6 days later. Images were acquired for 1 minute 
using small binning. (H) Mice in (G) were sacrificed and the lungs were imaged ex vivo for 
RLuc activity. Data summarize one representative out of 2 independently performed 
experiments. The signal intensity is shown as p/s/cm
2
/sr and depicted by a pseudocolor scale. 
 
Figure 4: RT-Rack detects the T-cell response to Cre recombinase-induced liver tumors 
in LTL x Alb-Cre mice. (A) 4-6 months old LTL x Alb-Cre mice (double transgenic, single 
transgenic and wild type mice) were imaged for FLuc to visualize tumor presence (1 second, 
small binning). In addition, single transgenic mice were imaged for 1 minute to visualize the 
leakiness reported to be detected in LTL mice. (B) Mice imaged in (A) were injected with R-
TCRI T cells and imaged at the indicated days for RLuc activity. (C) At day 7, mice were also 
imaged for both FLuc and RLuc signals simultaneously. A double transgenic mouse (left 
panel) and an Alb-Cre - single transgenic mouse (right panel) are shown. Top panels show 
RLuc signal (T cells) and middle panels FLuc signal (liver tumor). The overlay of both 
signals results in orange color and is shown in the bottom panels. (D-E) Liver (D) or total 
body (E) RLuc signal over time of Alb-Cre x LTL (♦), Alb-Cre (■), LTL (◊) and wild type 
(□) littermate mice. The experiment is representative of 2 independently performed 
experiments. (F) 4-6 months old LTL x Alb-Cre mice were imaged for FLuc activity twice 12 
days apart (d-24 and d-12, on 24 and 12 days before T cell injection.) to visualize tumor 
presence and progression. An Alb-Cre single transgenic mouse was used as a negative control. 
(G) At day 0, LTL x Alb-Cre mice from (F) were injected with R-TCRI T cells and imaged 
for RLuc activity at the indicated days post T cell transfer. Images were acquired for 1 minute, 
using small binning. (H) Graph showing the correlation between tumor burden (Fluc signal 
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from (F) on day -12) and T cell accumulation (RLuc signal from (G) on day 4). The signal 
intensity is shown as p/s/cm
2
/sr and depicted by a pseudocolor scale. 
 
Figure 5: RT-Rack based on the usage of TCR I transduced T cells detects T-cell 
response against Tag expressing tumors. (A) R-OT T cells were retrovirally transduced to 
express the Tag specific TCR I or were mock transduced with pMIG. Transduction rate was 
measured one day following the last transduction (at the day of T cell injection) with D
b
-
peptide I multimer (TCR I) or for GFP (pMIG). Cells were costained for CD8. (B) Rag
-/- 
 
mice were challenged with 16.113F tumor cells s.c. and were injected 49 days later with 10
5
 
OT-I-ChRLuc T cells transduced with TCR I (n=5) or pMIG (n=2) as a negative control and 
imaged for RLuc activity (T cells) at the indicated days. Images were acquired for 1 minute 
using small binning. (C) T cell signal over time from tumor sites. Data represent the summary 
of one representative out of 2 independently performed experiments. The signal intensity is 
shown as p/s/cm
2
/sr and depicted by a pseudocolor scale. 
 
Figure 6: TILs from LTL mice have less functional and more exhausted phenotype than 
TILs from Rag
-/-
 or C57BL/6 mice. Two weeks after 9.27P tumor challenge, Rag
-/-
 (■), 
LTL ( ) and C57BL/6 (□ ) mice were injected with R-TCRI T cells. After 7 days, 
splenocytes or TILs were isolated and analyzed for PD1 expression and the ability to respond 
to antigen-specific stimulation by flow cytometry. Shown are bar graphs summarizing the 
percentage of PD1 expression (A-C) and the MFI of  PD1
+
 cells from (A-C) in CD8
+
 Vβ7
+
 
from TILs (A, D) and splenocytes (B,C, E andF) ex vivo. (G-J) Cells from A-F were 
stimulated in vitro with peptide I of Tag. Shown are graphs summarizing the percentage of 
CD8
+
 Vβ7
+
 among TILs (G, J) and splenocytes (H-I) secreting IFN-γ (G-I) or granzyme B (J). 
Splenocytes from tumor-free littermates were used as control (C, F, I). TILs and splenocytes 
restimulated with gp33 as negative control did not secrete IFNγ or granzyme B (data not 
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schown). The experiments are representative of 2 independently performed sets of 
experiments.  
 
 
 
  
 
 
Figure 1  
140x106mm (300 x 300 DPI)  
 
 
  
 
 
Figure 2  
249x407mm (300 x 300 DPI)  
 
 
  
 
 
 
159x136mm (300 x 300 DPI)  
 
 
  
 
 
 
248x333mm (300 x 300 DPI)  
 
 
  
 
 
 
58x24mm (300 x 300 DPI)  
 
 
  
 
 
 
249x366mm (300 x 300 DPI)  
 
 
